Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Lung Cancer

Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S

doi: 10.1016/j.lungcan.2026.109305

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

CHRYSALIS-2: First-line amivantamab plus lazertinib demonstrates durable OS in atypical EGFR-mutated advanced NSCLC

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Lung Cancer

Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK

doi: 10.1016/j.lungcan.2025.108788

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Lung Cancer

Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC

doi: 10.1016/j.lungcan.2026.109302

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

Lung, Respiratory and Thoracic Cancer

Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

J Thorac Oncol

Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yang JC, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC

doi: 10.1016/j.jtho.2025.06.030

ELCC 2026

Lung, Respiratory and Thoracic Cancer

Related content

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

CHRYSALIS-2: First-line amivantamab plus lazertinib demonstrates durable OS in atypical EGFR-mutated advanced NSCLC

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC